Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth rate (AGR) of 0.90 per cent from 2.00 million in 2023 to 2.18 million in 2033 ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

ShareThe World Health Organisation (WHO) is assembling a Guideline Development Group (GDG) to craft recommendations for the ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

In Donald Trump’s 2019 State of the Union Address, he made “a commitment to eliminate the HIV epidemic in the United States ...